Quipt Announces That It Anticipates a Temporary Delay in the Filing of Financial Statements and Application for Management Cease Trade Order

3 years ago

CINCINNATI, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (“Quipt” or the “Company”) (NASDAQ:QIPT; TSXV:QIPT), a U.S. based…

XOMA Announces Evolution of Company Leadership and Succession Planning

3 years ago

Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director Company…

Singular Genomics Launches the G4 Sequencing Platform

3 years ago

– Next-generation sequencing platform will provide up to three times more data output per hour than other benchtop instruments, while…

uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease

3 years ago

~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one…

NeuroPace to Present at 40th Annual J.P. Morgan Healthcare Conference

3 years ago

MOUNTAIN VIEW, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on…

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia

3 years ago

Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with…

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant

3 years ago

The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of…

Kymera Discloses New KT-474 Clinical Data, Unveils New Development Program, Provides Oncology Pipeline as well as Platform and Discovery Updates, and Outlines 5-year Vision and Goals at 2021 R&D Day

3 years ago

Multiple Ascending Dose (MAD) data from KT-474 Phase 1 trial demonstrates near complete IRAK4 degradation in PBMC and skin, robust…

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

3 years ago

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline…

Update on the Phase 4 Confirmatory Study of ADUHELM®

3 years ago

CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an…